Galantamine

Plant alkaloid from the snowdrop (Galanthus nivalis) with a dual mechanism that none of Dylan's other cholinergics share — reversible AChE inhibition plus allosteric potentiation of α7 and α4β2 nicotinic acetylcholine receptors. A-tier evidence in mild-moderate Alzheimer's (FDA-approved 2001; Cochrane meta-analysis confirms cognitive + ADL benefit; comparable efficacy to donepezil). Healthy-adult cognition data is thin. The interesting use case for Dylan is lucid dreaming — 4-8 mg with the Wake-Back-To-Bed protocol has real signal in LaBerge 2018 systematic study (n=121, 42% lucid-dream rate vs 14% placebo). For chronic daily nootropic use: skip — citicoline already covers chronic choline, huperzine covers the AChEI role at lower regulatory burden, and α7 nAChR desensitization makes daily use blunt the unique mechanism. Verdict: WATCH-LIST. Optional 1-2× per month lucid-dreaming PRN at most.

Galantamine is a tertiary amine alkaloid originally isolated from Galanthus nivalis (common snowdrop) and Leucojum aestivum (summer snowflake) — Bulgarian researchers in the 1950s identified it from snowdrop bulbs as a treatment for poliomyelitis paralysis (Soviet bloc Rx as Nivalin from 1959). The Western pharma development as Reminyl/Razadyne for Alzheimer's came decades later (Janssen, FDA approval September 2001).

1. Reversible competitive AChE inhibition (primary mechanism by mass)

• Galantamine binds the catalytic site of acetylcholinesterase reversibly and competitively, slowing the breakdown of acetylcholine at central and peripheral synapses. This is the same fundamental action as donepezil, rivastigmine, and huperzine A.
• Potency is ~50× weaker than donepezil at AChE inhibition (IC50 ~800 nM vs ~6 nM for donepezil), and modestly weaker than huperzine A. The therapeutic dose (24 mg/day) reflects this — galantamine needs more milligrams for similar AChE coverage.
• Selectivity for AChE over butyrylcholinesterase (BChE): ~50:1 in favor of AChE. Donepezil is more selective (~1000:1); rivastigmine is the only non-selective one (inhibits both). Practical consequence: galantamine has slightly more peripheral cholinergic side effects than donepezil but less than rivastigmine.

2. Allosteric potentiation of nicotinic acetylcholine receptors (APL — the distinctive mechanism)

This is what makes galantamine different from every other AChEI on the market. Galantamine binds an allosteric site on the α7 nAChR (and α4β2, α3β4 to lesser degree) — distinct from the orthosteric ACh-binding site. Binding to the allosteric site does not directly activate the receptor, but it sensitizes the receptor to its agonists (ACh, choline itself, nicotine). Concretely:

• At a given synaptic ACh concentration, an α7 receptor pre-bound by galantamine produces a larger inward current (up to ~3-5× potentiation in patch-clamp studies; Maelicke 1995, 2001).
• α7 nAChRs are particularly choline-sensitive — choline is itself a partial agonist at α7. So galantamine + elevated synaptic choline (from citicoline / alpha-GPC / dietary choline) → potentiated α7 signaling without any nicotine present.
• α7 nAChRs are concentrated in prefrontal cortex, hippocampus, and cholinergic interneurons — the circuits underlying working memory, attention gating, and sensory filtering.
• α4β2 nAChRs are the high-affinity "nicotine-like" receptor — responsible for the cognitive enhancement reported with low-dose nicotine. Galantamine's APL action here partially mimics nicotine's cognitive effect without the addiction profile (no orthosteric agonism = no dopamine reward circuit recruitment in the same way).

Functional consequence for working memory + cognition:

• The α7 + α4β2 potentiation is the leading hypothesis for galantamine's separation from donepezil/rivastigmine on certain cognitive measures — particularly attention, executive function, and possibly sensory gating (P50, mismatch negativity).
• The α7 mechanism is also why galantamine has been trialed in schizophrenia adjunct (sensory gating deficit, P50 abnormality) — the α7 hypothesis of cognitive deficits in schizophrenia (Freedman 2007 and follow-on work).

3. The "cholinergic substrate × allosteric potentiation" stack logic

This is Dylan-relevant. Galantamine + a choline donor (citicoline, alpha-GPC, dietary choline) is mechanistically synergistic in a way that galantamine alone or choline alone is not:

• More choline available → more substrate for ACh synthesis (citicoline / alpha-GPC role).
• Galantamine inhibits ACh breakdown → ACh stays elevated longer (AChEI role).
• Galantamine sensitizes α7 nAChRs to choline directly (APL role) → even non-converted free choline contributes to α7 signaling.

The trade-off: this same multiplied cholinergic loading is what produces side effects (N/V/D, sleep disruption, vivid dreams). Dylan's V4 already includes citicoline 500 mg daily — adding galantamine on top of that is mechanistically meaningful but also multiplicatively more cholinergic.

4. Other documented effects

• Mild allosteric effect at GABA-A receptors (low affinity; not clinically relevant at therapeutic doses).
• Anti-inflammatory via the cholinergic anti-inflammatory pathway (vagal α7-mediated) — α7 stimulation on macrophages reduces TNF-α release. This is the basis for some sepsis / colitis preclinical work (Tracey lab) and the broader interest in α7 agonists/PAMs as anti-inflammatory tools. Likely not magnitude-relevant for Dylan at lucid-dreaming-PRN doses.
• Possible neuroprotection via α7 nAChR — α7 activation has been shown to reduce amyloid-β toxicity in vitro and in transgenic mouse models (Wang 2003, Liu 2020). Underpins the interest in galantamine as a disease-modifying agent in AD, distinct from its symptomatic effect — though clinical trials have not clearly shown disease modification.